Literature DB >> 1686755

Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice.

R Young1, D N Johnson.   

Abstract

The effects of the optical isomers of zacopride were assessed in mice in a fully automated two-compartment light/dark apparatus. A significant increase in time spent in the lit area was used as an indication of anxiolytic-like action. Intraperitoneal (i.p.) doses of R(+)-zacopride from 0.00001 to 10.0 mg/kg and S(-)-zacopride from 0.01 to 1.0 mg/kg produced significant anxiolytic-like activity. Oral (p.o.) doses of the R(+) isomer from 0.00001 to 10.0 mg/kg and S(-)isomer from 0.1 to 1.0 mg/kg also generated antianxiety-like action. In addition, R(+)-zacopride (0.0001 mg/kg) was evaluated for time course effects after i.p. and p.o. administration. By either route of injection, the onset to action of R(+)-zacopride was 0.5 h, while the duration of effect was greater than or equal to 16 h. It was concluded that R(+)-zacopride is a potent and long-acting drug and that it is principally responsible for the anxiolytic-like activity of racemic zacopride.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686755     DOI: 10.1016/0014-2999(91)90338-q

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.

Authors:  J E Barrett; K E Vanover
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

2.  Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1999-05       Impact factor: 3.996

Review 3.  Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence.

Authors:  N Andrews; S E File
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.

Authors:  I Artaiz; G Romero; A Zazpe; A Monge; J M Calderó; J Roca; B Lasheras; J Del Río
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

5.  Are there changes in sensitivity to 5-HT3 receptor ligands following chronic diazepam treatment?

Authors:  N Andrews; S E File
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors.

Authors:  Neema K Pithia; Christopher Liang; Xiang-Zuo Pan; Min-Liang Pan; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2016-03-08       Impact factor: 2.823

7.  Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.

Authors:  N M Barnes; C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.

Authors:  C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

9.  The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.

Authors:  D J Bill; J Coleman; I Hallett; V C Middlefell; K F Rhodes; A Fletcher
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

10.  Ondansetron improves cognitive performance in the Morris water maze spatial navigation task.

Authors:  D J Fontana; S E Daniels; C Henderson; R M Eglen; E H Wong
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.